Physician profile
Alexander Barsouk
NPI 1114929544
$673,806.02
in general payments reported to CMS, 2019-2025
54 companies · $73K in 2025
The $73K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160K · 2020: $53K · 2021: $78K · 2022: $102K · 2023: $86K · 2024: $123K · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200K · Travel and Lodging: $42K · Consulting Fee: $27K · Food and Beverage: $8,831 · Honoraria: $3,810 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $199,826.00 |
| Travel and Lodging | $42,146.24 |
| Consulting Fee | $26,582.50 |
| Food and Beverage | $8,831.04 |
| Honoraria | $3,810.00 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $269,236.64 | 2019-2025 | Opdivo |
| Daiichi Sankyo INC. | $264,792.66 | 2019-2025 | Injectafer, Enhertu, Vanflyta |
| Exelixis INC. | $17,535.52 | 2019-2025 | Cabometyx |
| Pfizer INC. | $14,788.37 | 2019-2025 | |
| Genzyme Corporation | $14,496.02 | 2019-2023 | |
| Lilly USA, LLC | $14,324.69 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $8,807.15 | 2019-2024 | |
| Pharmacosmos Therapeutics INC. | $7,353.79 | 2020-2023 | Monoferric |
| Acrotech Biopharma INC. | $6,637.21 | 2022-2025 | Beleodaq |
| Cti Biopharma Corp. | $6,500.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $6,250.15 | 2019-2025 | Tezspire, Imfinzi, Enhertu |
| Seagen INC. | $6,114.90 | 2019-2023 | Padcev |
| Beigene USA, INC. | $5,923.98 | 2020-2025 | Brukinsa |
| Janssen Biotech, INC. | $4,589.82 | 2019-2025 | Erleada, Rybrevant, Akeega |
| Takeda Pharmaceuticals U.S.A., INC. | $4,175.61 | 2019-2025 | Fruzaqla, Alunbrig, Iclusig |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,139.37 | 2019-2022 | |
| Avyxa Pharma, LLC | $3,368.70 | 2025 | |
| Incyte Corporation | $2,614.02 | 2019-2025 | Jakafi, Niktimvo |
| Dova Pharmaceuticals | $2,250.00 | 2020 | |
| Blueprint Medicines Corporation | $1,512.00 | 2021 | |
| R-Pharm US LLC | $1,495.64 | 2019 | |
| Taiho Oncology, INC. | $1,353.02 | 2020-2025 | |
| Athenex Pharmaceutical Division, LLC | $1,250.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $913.63 | 2019 | |
| Coherus Oncology, INC. | $910.22 | 2021 | |
| Novartis Pharmaceuticals Corporation | $401.45 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $363.75 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novocure Gmbh | $200.00 | 2022 | |
| Glaxosmithkline, LLC. | $183.60 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Genentech USA, INC. | $150.95 | 2019 | |
| Celgene Corporation | $150.46 | 2019-2025 | Opdivo, Reblozyl |
| Sumitomo Pharma America, INC. | $101.33 | 2024-2025 | Orgovyx |
| Eisai INC. | $92.04 | 2024-2025 | |
| Stemline Therapeutics INC. | $85.56 | 2024-2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $73.96 | 2021-2025 | Onivyde, Tazverik |
| Amgen INC. | $57.95 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $52.80 | 2019-2021 | |
| Aveo Pharmaceuticals, INC. | $50.85 | 2024-2025 | |
| Adc Therapeutics America, INC. | $50.13 | 2024-2025 | |
| Genmab U.S., INC. | $43.11 | 2024-2025 | Epkinly |
| Geron Corporation | $42.83 | 2025 | Rytelo |
| Tesaro, INC. | $40.62 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $37.92 | 2022-2024 | Libtayo |
| Medtronic, INC. | $35.00 | 2023 | Gia |
| Array Biopharma INC | $34.87 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Deciphera Pharmaceuticals INC. | $33.01 | 2024-2025 | Qinlock, Romvimza |
| Beone Medicines USA, INC. | $32.34 | 2025 | Tevimbra |
| Tempus Ai, INC | $30.41 | 2024 | |
| Sobi, INC | $27.90 | 2024 | |
| Myovant Sciences INC. | $23.93 | 2022 | |
| Rigel Pharmaceuticals, INC. | $22.89 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Janssen Pharmaceuticals, INC | $21.74 | 2024 | Xarelto |
| Amag Pharmaceuticals, INC. | $16.56 | 2021 | |
| Karyopharm Therapeutics INC. | $14.95 | 2024 | Xpovio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Barsouk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.